Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21578793 | 0.84 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10837934 | 0.84 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL12189970 | 0.83 | TDP1 (0.40) | ALDH1A1TSHRLMNA | |
| SCHEMBL7903373 | 0.83 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13349132 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28885641 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28367591 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1749919 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11798942 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL5607500 | 0.82 | NAAA (0.38) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778208-A | Hansenula polymorpha (Hanseniaspora opuntiae) strain 52 and application, product and method thereof | 西北农林科技大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117778208-A | Hansenula polymorpha (Hanseniaspora opuntiae) strain 52 and application, product and method thereof | 西北农林科技大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-09-21 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225761-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| EP-0717053-A2 | Catalyst for olefin polymerization and process for producing polyolefin using the same | JAPAN POLYOLEFINS CO., LTD. (JP) | 1996-06-19 | — | — | EP | disclosed |
| EP-0704424-A1 | 3-alkoxypropionic ester derivative, olefin polymerization catalyst, and process for preparation of polyolefin | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1996-04-03 | — | — | EP | disclosed |
| US-5476825-A | Consists of magnesium, titanium and halogen compounds, an organoaluminum compound, a reaction product of organoaluminum or organoboron compound with organosilicon compound | SHOWA DENKO K.K. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0383346-B1 | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | SHOWA DENKO KK (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-5407883-A | Containing magnesium, titanium, aluminum and silicon compounds including polymeric aluminum and alumoxanes | SHOWA DENKO K.K. (JP) | 1995-04-18 | — | — | US | disclosed |
| EP-0640624-A1 | Catalyst for polymerization of olefin and process for the preparation of olefin polymer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1995-03-01 | — | — | EP | disclosed |
| EP-0578473-A1 | Catalyst for polymerization of olefin and process for producing olefin polymer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5041403-A | Magnesium, titanium, halogen, ester compound, and organic aluminum compound | SHOWA DENKO K.K. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0383346-A2 | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-08-22 | — | — | EP | disclosed |
| US-3973013-A | Substituted S-carboxymethyl-(thiono)-(di)-thiol-phosphonic acid esters and ester-amides and insecticidal composition and method | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | GAA 1315/4885MGAM 1795/4885SI 305/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GAA 904/4885MGAM 1728/4885SI 2678/4885 |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GAA 1085/4885MGAM 1523/4885SI 2749/4885 |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NUDT15, NME4 | GAA 3364/4885MGAM 3751/4885SI 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.